Continuous glucose monitor

British Columbia First Province to Cover Dexcom G6 Continuous Glucose Monitoring System for People With Type 1 and Type 2 Diabetes on Intensive Insulin Therapy

Retrieved on: 
Friday, June 11, 2021
Diabetes, Medical devices, Health, Other Technology, Technology, Medicine, Clinical medicine, Diabetes, Medical monitoring, Blood glucose monitoring, Dexcom, Diabetes management, Continuous glucose monitor, Intensive insulin therapy, Insulin, Type 1 diabetes, Insulin pump

View the full release here: https://www.businesswire.com/news/home/20210611005428/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210611005428/en/
    The Dexcom G6 CGM System now covered by BC PharmaCare for people living with diabetes who are on intensive insulin therapy.
  • Diabetes.
  • Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial.
  • Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes.

Senseonics Announces Results of the PROMISE Study Demonstrating Strong Accuracy of 180 Day CGM Sensor

Retrieved on: 
Thursday, June 3, 2021
Medical devices, Health, Diabetes, Research, Science, Biotechnology, Sensor, Transducers, Medicine, Medical monitoring, Equipment, Technology, Continuous glucose monitor, Blood glucose monitoring, Eversense, Senseonics, EVERSENSE, SENSEONICS

Results were presented for both the primary sensor and for a secondary sensor with modified chemistry (referred to as the SBA sensor) in a subset of study participants.

Key Points: 
  • Results were presented for both the primary sensor and for a secondary sensor with modified chemistry (referred to as the SBA sensor) in a subset of study participants.
  • The accuracy profile demonstrated by Eversense in the PROMISE Study validates the role that long-term implantable CGM systems can play in helping people manage their glucose levels.
  • We are very pleased with the results of the PROMISE Study which demonstrate an excellent safety and accuracy profile for the 180-day sensor.
  • Senseonics' CGM Systems, Eversense and Eversense XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.

Dexcom Looks to the Future of Continuous Glucose Monitoring

Retrieved on: 
Thursday, June 3, 2021
Diabetes, Medical devices, Health, Other Technology, Technology, Medicine, Medical technology, Medical equipment, Dexcom, Medical monitoring, Continuous glucose monitor, Blood glucose monitoring, Insulin, CGM, Diabetes, Animas Corporation

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the publication and presentation of two new studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).

Key Points: 
  • DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the publication and presentation of two new studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).
  • With the publication of the MOBILE data, Dexcom has now demonstrated significant outcomes driven by its CGM technology in randomized controlled trials across the full spectrum of insulin use in people with diabetes.
  • The clinical benefits of Dexcom CGM were seen across all patient demographics regardless of age, education, numeracy or socioeconomic status, said David Price, MD, vice president of medical affairs at Dexcom.
  • DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients.

Continuous glucose monitors help manage type 2 diabetes

Retrieved on: 
Wednesday, June 2, 2021
Medicine, Clinical medicine, Diabetes, Health, Blood glucose monitoring, Continuous glucose monitor, Insulin, Type 1 diabetes, Blood sugar level, Diabetes management, Glycated hemoglobin

The retrospective, comparative effectiveness study included 5,673 patients with type 1 diabetes and 36,080 patients with type 2 diabetes treated with insulin who were self-monitoring their blood glucose.

Key Points: 
  • The retrospective, comparative effectiveness study included 5,673 patients with type 1 diabetes and 36,080 patients with type 2 diabetes treated with insulin who were self-monitoring their blood glucose.
  • Between January 2015 and December 2019, on the recommendation of their doctors, 3,462 patients with type 1 diabetes and 344 with type 2 diabetes began using continuous glucose monitors.
  • "This study shows that continuous glucose monitors helped people stay close to their glucose targets without going too low."
  • Since 2017, Medicare has covered the cost of continuous glucose monitors for patients with diabetes who met certain qualifications.

Global Glucose Monitoring Market (2020 to 2027) - Featuring Abbott Laboratories, Roche Holdings and Sinocare Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, May 28, 2021
Diabetes, Health, Medical devices, Medicine, Clinical medicine, Medical specialties, Blood tests, Diabetes, Medical monitoring, Blood glucose monitoring, Glucose, Continuous glucose monitor, Blood sugar level, Monitoring, Ambulatory glucose profile

Glucose Monitoring consists of products that are essential for measuring glucose levels in diabetes patients.

Key Points: 
  • Glucose Monitoring consists of products that are essential for measuring glucose levels in diabetes patients.
  • According to analysis, the Glucose Monitoring global market is expected to grow at a low single digit CAGR from 2020 to 2027 reach $15,321.8 million by 2027.
  • Invasive products are further divided into Self-monitoring blood glucose (SMBG) and continuous glucose monitoring (CGM) products.
  • The Self glucose monitoring products are further classified into blood glucose monitors, blood glucose test strips, lancets and others.

Dexcom Announces Upcoming Conference Presentation

Retrieved on: 
Thursday, May 27, 2021
Biotechnology, Diabetes, Health, Medical devices, Medical technology, Medicine, Health, Dexcom, Diabetes, Continuous glucose monitor, Medical monitoring, Blood glucose monitoring, Diabetes management, DXCM

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:
    Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present on behalf of the company at the William Blair 41st Annual Growth Stock Conference to be held virtually on Tuesday, June 1, 2021 at 12:00pm (CDT).
  • The webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com/ and will be archived there for future reference.
  • DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products.
  • By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.

RAMQ Now Offers Provincial Coverage of The Dexcom G6 Continuous Glucose Monitoring System for People Living with Type 1 Diabetes in Quebec

Retrieved on: 
Wednesday, May 26, 2021
Medicine, Medical technology, Diabetes, Medical equipment, Dexcom, Continuous glucose monitor, Medical monitoring, Blood glucose monitoring, Diabetes management, CGM, Caregiver, Type 1 diabetes

This coverage expansion is in line with Dexcom's mission to make it easier for people living with diabetes in Quebec to experience the benefits of using a CGM system for their diabetes management.

Key Points: 
  • This coverage expansion is in line with Dexcom's mission to make it easier for people living with diabetes in Quebec to experience the benefits of using a CGM system for their diabetes management.
  • This announcement marks a significant accomplishment in increasing access to life changing technology used in the management of type 1 diabetes.
  • "With continuous data to help monitor her glucose levels, Dexcom G6 enables us and her caregivers to take necessary actions to manage her condition.
  • For more information about the coverage criteria for RAMQ, please visit
    Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems.

Global Insulin Pens, Syringes, Pumps and Injectors Market Report 2021: Market is Expected to Surpass $25 Billion in 2025 - Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 21, 2021
Health, Pharmaceutical, Medicine, Clinical medicine, Diabetes, Medical monitoring, Diabetes management, Peptide hormones, Recombinant proteins, Insulin, Blood glucose monitoring, Glucose meter, Continuous glucose monitor, Insulin pump

The fear of injections causes anxiety in some patients thus causing them to avoid the use of insulin injections and being inconsistent in their insulin uptake.

Key Points: 
  • The fear of injections causes anxiety in some patients thus causing them to avoid the use of insulin injections and being inconsistent in their insulin uptake.
  • It is a diabetes management device that automatically monitors glucose and provides appropriate level insulin doses needed.
  • This pump uses interoperable technology that allows patients to customize their diabetes management devices according to their preferences.
  • These devices contain automated insulin dosing systems, continuous glucose monitors, blood glucose meters, or other electronic devices.\n'

Nemaura Medical to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021

Retrieved on: 
Tuesday, May 4, 2021
Medicine, Health, Clinical medicine, Nemaura Medical, Diabetes, Medical monitoring, Blood glucose monitoring, Continuous glucose monitor, Medical device, XC2, Prediabetes

b'Loughborough, England, May 04, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.\nChief Executive Officer Faz Chowdhury, Ph.D. will deliver his corporate presentation at 3:15pm ET on May 14, 2021.\nInvestors can also request a one-on-one meeting with Dr. Chowdhury to be arranged following the conclusion of the conference.\nInvestors can register for the conference here: https://www.benzinga.com/events/small-cap/global/\nNemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.

Key Points: 
  • b'Loughborough, England, May 04, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.\nChief Executive Officer Faz Chowdhury, Ph.D. will deliver his corporate presentation at 3:15pm ET on May 14, 2021.\nInvestors can also request a one-on-one meeting with Dr. Chowdhury to be arranged following the conclusion of the conference.\nInvestors can register for the conference here: https://www.benzinga.com/events/small-cap/global/\nNemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.
  • The company is currently commercializing sugarBEAT\xc2\xae and proBEAT\xe2\x84\xa2.
  • sugarBEAT\xc2\xae, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes.
  • Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT\xc2\xae to the U.S. FDA.

Supersapiens Closes $13.5 Million in Early-Stage Funding

Retrieved on: 
Tuesday, April 27, 2021
Medicine, Medical monitoring, Blood glucose monitoring, Continuous glucose monitor, CGM, Glucose, Biosensor, Health, Clinical medicine

Supersapiens also attracted global investment from CM Ventures, Rubix Ventures, Swiss Startup Group, and Wahoo Fitness.\n"Sports continuous glucose monitoring (CGM) is an absolute game changer for all athletes.

Key Points: 
  • Supersapiens also attracted global investment from CM Ventures, Rubix Ventures, Swiss Startup Group, and Wahoo Fitness.\n"Sports continuous glucose monitoring (CGM) is an absolute game changer for all athletes.
  • As an athlete, I am intimately aware of the impact glucose has on the ability to achieve your goals.
  • For markets where Supersapiens has yet to be released, athletes can secure their spot on the waitlist .
  • When used with a compatible product, the biosensor allows athletes to correlate their glucose levels and their athletic performance.